James Loerop

CIK: 0001781549

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)11 (45.8%)

Derivative conversions

Awards (A)5 (20.8%)

Compensation grants

Other (G, F, J, C, D, …)8 (33.3%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

ACRS

Aclaris Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (24 total)

ACRS
Aclaris Therapeutics, Inc.
Feb 3, 2026
Exercise(M)
Direct
20.9K shares-
ACRS
Aclaris Therapeutics, Inc.
Feb 3, 2026
Tax Payment(F)
Direct
5.9K shares at avg. $3.47$21K
ACRS
Aclaris Therapeutics, Inc.
Feb 2, 2026
Award(A)
Restricted Stock Units
Direct
97.7K shares-
ACRS
Aclaris Therapeutics, Inc.
Feb 2, 2026
Award(A)
Employee Stock Option (Right to Buy)
Direct
341.9K shares-
ACRS
Aclaris Therapeutics, Inc.
Feb 1, 2026
Exercise(M)
Direct
7.5K shares-
ACRS
Aclaris Therapeutics, Inc.
Feb 1, 2026
Tax Payment(F)
Direct
10.7K shares at avg. $3.51$38K
ACRS
Aclaris Therapeutics, Inc.
Feb 1, 2026
Exercise(M)
Direct
11.3K shares-
ACRS
Aclaris Therapeutics, Inc.
Feb 1, 2026
Exercise(M)
Direct
14.8K shares-
ACRS
Aclaris Therapeutics, Inc.
Jan 2, 2026
Tax Payment(F)
Direct
6.2K shares at avg. $2.88$18K
ACRS
Aclaris Therapeutics, Inc.
Jan 2, 2026
Exercise(M)
Direct
18.2K shares-
ACRS
Aclaris Therapeutics, Inc.
Dec 31, 2025
Exercise(M)
Direct
73.8K shares-
ACRS
Aclaris Therapeutics, Inc.
Dec 31, 2025
Tax Payment(F)
Direct
34K shares at avg. $3.01$102K
ACRS
Aclaris Therapeutics, Inc.
Feb 3, 2025
Award(A)
Restricted Stock Units
Direct
83.5K shares-
ACRS
Aclaris Therapeutics, Inc.
Feb 3, 2025
Award(A)
Employee Stock Option (Right to Buy)
Direct
292.3K shares-
ACRS
Aclaris Therapeutics, Inc.
Feb 1, 2025
Tax Payment(F)
Direct
16K shares at avg. $2.48$40K
ACRS
Aclaris Therapeutics, Inc.
Feb 1, 2025
Tax Payment(F)
Direct
15.4K shares at avg. $2.48$38K
ACRS
Aclaris Therapeutics, Inc.
Feb 1, 2025
Exercise(M)
Direct
11.3K shares-
ACRS
Aclaris Therapeutics, Inc.
Feb 1, 2025
Exercise(M)
Direct
7.5K shares-
ACRS
Aclaris Therapeutics, Inc.
Feb 1, 2025
Exercise(M)
Direct
14.8K shares-
ACRS
Aclaris Therapeutics, Inc.
Jan 2, 2025
Award(A)
Restricted Stock Units
Direct
55K shares-
ACRS
Aclaris Therapeutics, Inc.
Jan 2, 2025
Exercise(M)
Direct
18.2K shares-
ACRS
Aclaris Therapeutics, Inc.
Jan 2, 2025
Tax Payment(F)
Direct
8.6K shares at avg. $2.48$21K
ACRS
Aclaris Therapeutics, Inc.
Dec 31, 2024
Tax Payment(F)
Direct
32.1K shares at avg. $2.48$80K
ACRS
Aclaris Therapeutics, Inc.
Dec 31, 2024
Exercise(M)
Direct
73.8K shares-

		Type	Shares	Price		Ownership
Feb 3, 2026	ACRS Aclaris Therapeutics, Inc.	Exercise(M)	20,875	-	$0	Direct
Feb 3, 2026	ACRS Aclaris Therapeutics, Inc.	Tax Payment(F)	5,937	$3.47	$20,601	Direct
Feb 2, 2026	ACRS Aclaris Therapeutics, Inc.	Award(A) Restricted Stock Units	97,700	-	-	Direct
Feb 2, 2026	ACRS Aclaris Therapeutics, Inc.	Award(A) Employee Stock Option (Right to Buy)	341,900	-	-	Direct
Feb 1, 2026	ACRS Aclaris Therapeutics, Inc.	Exercise(M)	7,500	-	$0	Direct
Feb 1, 2026	ACRS Aclaris Therapeutics, Inc.	Tax Payment(F)	10,686	$3.51	$37,508	Direct
Feb 1, 2026	ACRS Aclaris Therapeutics, Inc.	Exercise(M)	11,250	-	$0	Direct
Feb 1, 2026	ACRS Aclaris Therapeutics, Inc.	Exercise(M)	14,750	-	$0	Direct
Jan 2, 2026	ACRS Aclaris Therapeutics, Inc.	Tax Payment(F)	6,171	$2.88	$17,772	Direct
Jan 2, 2026	ACRS Aclaris Therapeutics, Inc.	Exercise(M)	18,150	-	$0	Direct
Dec 31, 2025	ACRS Aclaris Therapeutics, Inc.	Exercise(M)	73,750	-	$0	Direct
Dec 31, 2025	ACRS Aclaris Therapeutics, Inc.	Tax Payment(F)	33,994	$3.01	$102,322	Direct
Feb 3, 2025	ACRS Aclaris Therapeutics, Inc.	Award(A) Restricted Stock Units	83,500	-	-	Direct
Feb 3, 2025	ACRS Aclaris Therapeutics, Inc.	Award(A) Employee Stock Option (Right to Buy)	292,300	-	-	Direct
Feb 1, 2025	ACRS Aclaris Therapeutics, Inc.	Tax Payment(F)	15,980	$2.48	$39,630	Direct
Feb 1, 2025	ACRS Aclaris Therapeutics, Inc.	Tax Payment(F)	15,447	$2.48	$38,309	Direct
Feb 1, 2025	ACRS Aclaris Therapeutics, Inc.	Exercise(M)	11,250	-	-	Direct
Feb 1, 2025	ACRS Aclaris Therapeutics, Inc.	Exercise(M)	7,500	-	-	Direct
Feb 1, 2025	ACRS Aclaris Therapeutics, Inc.	Exercise(M)	14,750	-	-	Direct
Jan 2, 2025	ACRS Aclaris Therapeutics, Inc.	Award(A) Restricted Stock Units	55,000	-	-	Direct
Jan 2, 2025	ACRS Aclaris Therapeutics, Inc.	Exercise(M)	18,150	-	$0	Direct
Jan 2, 2025	ACRS Aclaris Therapeutics, Inc.	Tax Payment(F)	8,575	$2.48	$21,266	Direct
Dec 31, 2024	ACRS Aclaris Therapeutics, Inc.	Tax Payment(F)	32,089	$2.48	$79,581	Direct
Dec 31, 2024	ACRS Aclaris Therapeutics, Inc.	Exercise(M)	73,750	-	$0	Direct

1-24 of 24 transactions

About Loerop James

Loerop James (SEC CIK 0001781549) files insider reports with the SEC as Chief Business Officer of Aclaris Therapeutics, Inc. (ACRS).

Signal8 holds 8 ownership filings by Loerop James, all Form 4s, filed between Jan 3, 2025 and Feb 6, 2026. Those filings report 24 transactions, from Dec 31, 2024 to Feb 3, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Loerop James's filings is in WAYNE, PA.

Recent filings by Loerop James

Feb 3, 2026: Option exercise of ACRS shares (Form 4, code M).
Feb 3, 2026: Tax withholding of ACRS shares (Form 4, code F).
Feb 2, 2026: Grants or awards of ACRS derivative securities (2 lines, Form 4, code A).
Feb 1, 2026: Option exercise of ACRS shares (Form 4, code M).
Feb 1, 2026: Tax withholding of ACRS shares (Form 4, code F).

Other insiders filing for Aclaris Therapeutics, Inc. (ACRS)

Kolbeck Roland Wilhelm, Chief Scientific Officer
SCHIFF ANDREW N, Director
Mehra Anand, Director
Molineaux Christopher P., Director
Humphries William D., Director
MILANO VINCENT, Director

How to read Form 4 transaction codes